A 30-year-old man presented with sagittal sinus thrombosis. He had a history of multiple thrombotic events since adolescence, and his father had had a similar history. Laboratory studies revealed the complete absence of free protein S in his plasma. Protein S deficiency, an autosomal dominant disorder, is an identifiable cause of cerebral thrombosis. The literature and our experience with this case suggest that long-term anticoagulant therapy may prevent thrombotic episodes in patients with this disorder. (Stroke 1990;21:633-636)
C erebral venous thrombosis may be due to a variety of pathologic conditions, 1 yet 20-24% of cases are still considered idiopathic in large series. 2 - 3 We describe cerebral venous thrombosis in a patient with protein S deficiency. Protein S is a vitamin K-dependent plasma protein functioning as a cofactor for the anticoagulant activity of activated protein C. Deficiencies of protein S and protein C are inherited diseases causing hypercoagulable states responsible for multiple episodes of superficial and deep venous thrombosis and pulmonary emboli.
The two aims of our paper are to describe an infrequently recognized cause of cerebral venous thrombosis and to stress the need for accurate diagnosis of this rare hypercoagulable state, the serious complications of which may seemingly be prevented by chronic oral anticoagulation.
Case Report
A 30-year-old white man was brought to the emergency room shortly after a first generalized tonicclonic seizure witnessed by his coworkers. Two hours after the seizure, his mental status and neurologic examination were normal. Noncontrast computed tomography (CT) showed a small hematoma in the right frontal apex with minimal edema, no subarachnoid blood, and no mass effect. The patient was admitted for further evaluation.
The patient gave a history of multiple episodes of superficial and deep venous thrombosis during the previous 15 years. There were also two episodes (one documented and one probable) of pulmonary embolus. Previous work-ups had failed to reveal the cause of his hypercoagulable state. The patient's father, who died in 1979, had shown the same predisposition to superficial and deep venous thromboses during his life. A paternal uncle and the uncle's daughter were also possibly affected.
During hospitalization, the patient's erythrocyte sedimentation rate was 8 mm/hr, and a complete blood count revealed 12.8xlO 9 leukocytes and 5.5 xlO 12 erythrocytes per liter. His hemoglobin concentration was 144 g/1, there were 238x10' platelets per liter, and his hematocrit was 42.3%. The differential count was normal. The glucose concentration was 174 mmol/1, blood urea nitrogen 6.07 mmol/1, creatinine 97.24 mmol/1, uric acid 387 mmol/1, calcium 2.35 mmol/1, and phosphorus 0.87 mmol/1. The total bilirubin, serum glutamic oxaloacetic transaminase, serum glutamic pyruvate transaminase, alkaline phosphatase, and cholesterol concentrations were all normal.
Bilateral carotid angiography performed 4 days after admission revealed complete occlusion of the anterior compartment of the superior sagittal sinus with multiple, dilated cortical veins. No evidence of arteriovenous malformation was noted ( Figure 1 ).
The results of electroencephalography performed on the first and tenth days of hospitalization were normal. Contrast CT performed 10 days after admission showed resolution of the right intracerebral hematoma and evidence of progression of thrombosis in the anterior third of the superior sagittal sinus (Figure 2) .
Coagulation studies were performed using standard techniques with commercially available reagents and pooled normal, platelet-poor plasma as the sey) diluted to a conce ntration of 5 thrombin units/ ml, Thrombowelco Test (Burroughs Wellcome Co., Triangle Park, North Carolina), Nor-Partigen Antithrombin III and Fibrinogen kits, factor IX-deficient plasma (Dade), and factor VII-and factor Xdeficient substrates (Dade). The lupus anticoagulant was assayed using the modified Russell's viper venom method. 6 Protein C was assayed using the immunologic method, and protein S studies using crossed immunoelectrophoresis and quantitative methods were performed as previously described. The prothrombin time was 12.9 (control 12.1) seconds, the kaolin-activated partial thromboplastin time was 28.9 (control 33.5) seconds, the thrombin time was 9.3 (control 11.9) seconds, the thrombinclottable fibrinogen concentration was 2.4 g/1, the immunologically determined fibrinogen concentration was 2.9 g/1, and the fibrin degradation product concentrations were <40xl0~9 g/1. The antithrombin III concentration was 0.27 (normal range 0.22-0.39) g/1. Factor VII was 100%, factor IX 125% and factor X 98%. The protein C level was 80% (normal range 65-150%). The total protein S concentration was 11.5 (normal range 15.2-24.5) mg/1, and the free (functional) protein S concentration was 1.75 (normal range 5.2-10.2) mg/1. The C4b binding protein concentration was 217 (normal range 140-242) mg/1. The patient's crossed immunoelectrophoresis pattern is shown in Figure 3 .
Results of neurologic examinations remained normal throughout hospitalization. Once the diagnosis of protein S deficiency was secured, the patient was placed on warfarin. 
Discussion
In this patient, a single generalized tonic-clonic seizure revealed a small right frontal hematoma. Sagittal sinus thrombosis was documented angiographically, and the hematoma was tentatively attributed to rupture of a congested intraparenchymal vein. The unusual neuroradiologic findings have been presented elsewhere. 9 The clinical course was benign.
This patient gave a striking history of multiple venous thromboses during the previous 15 years and reported a similar history in his father. These anamnestic findings are typical of protein S deficiency, 7 ' 10 "
12 and are indistinguishable from those of antithrombin III deficiency and protein C deficiency, other known causes of dominantly inherited hypercoagulable states. 13 The laboratory studies excluded antithrombin III deficiency and protein C deficiency, as well as dysfibrinogenemia, and were compatible with protein S deficiency. Although deficient tissue plasminogen activator synthesis or release from vessel walls, another possible mechanism of hypercoagulability, were not excluded, they do not seem likely. 14 Cerebral venous thrombosis is a rare complication of these thrombotic diseases. It has been reported in patients with antithrombin III deficiency 2 -15 and protein C deficiency 16 but has been only briefly mentioned in patients with protein S deficiency.
11
- 17 The patient alluded to in Reference 11 was a 35-year-old woman who developed stupor and hemiparesis 2 weeks post partum; carotid angiography established the diagnosis of superior sagittal sinus thrombosis, and the patient was anticoagulated and recovered completely (E. Briet, personal communication). Engesser and colleagues 11 studied 71 subjects heterozygous for protein S deficiency; 39 (55%) had one or more thrombotic event and of these 39, 30 (42% of the total group) had multiple thrombotic manifestations including superficial and deep venous thromboses and pulmonary emboli. Other manifestations of thrombotic disease were uncommon. Of interest is that 74% of the symptomatic group were males, yet none of the 71 patients had symptomatic arterial thrombotic disease before the age of 50 years. In the patients of Engesser et al, 11 no recurrent thrombosis was seen in subjects adequately anticoagulated, suggesting that oral anticoagulation is an effective way to prevent thromboses in patients with protein S deficiency. Two patients were kept on oral anticoagulants for 15 and 21 years and had no thrombotic events during those years. The situation was similar in our patient during his 2-year follow-up.
Warfarin-induced hemorrhagic skin necrosis did not occur in 30 protein S-deficient patients reported by Engesser et al, 11 whereas it has been reported during the starting phase of oral anticoagulation in patients with protein C deficiency. 18 It may be indicated to identify situations resulting in increased risk for thrombosis (such as immobilization, surgery, or pregnancy) in protein S-deficient patients so that preventive anticoagulation can be considered. Warfarin therapy being contraindicated during pregnancy, a patient with protein S deficiency was successfully managed by Rose et al 19 with prophylactic heparin therapy and elective pregnancy termination. Finally, recognition of protein S deficiency, in which the first clinical manifestations usually occur during the second or third decade of life, 11 should result in genetic counseling when appropriate.
Protein S exists in the plasma in two forms, a free form and a form complexed with C4b binding protein; only the free form is functionally active. 7 Two types of protein S deficiency have been identified. Type I is characterized by functional deficiency, with normal or mildly reduced plasma protein S concentrations assessed by conventional immunologic methods. These individuals have all or most of their protein S bound to C4b binding protein, with little or no free form, as in our patient. Patients with Type II deficiency, less commonly seen, have little or no protein S, either bound or free. This emphasizes the need for both a functional assay and a means of assessing the distribution of protein S between the bound and free forms for the accurate diagnosis and classification of individuals with deficiencies. 
